摘要:

Twenty-two patients with metastatic breast carcinoma were treated with a combination of cisplatin (100 mg/m2 i.v. day 1) and etoposide (100 mg/m2 i.v. days 1-3). Eligible patients had measurable disease with normal organ functions, performance status < 3, age < 70 years and no previous chemotherapy for metastatic disease. Twenty patients were assessable for response. Objective responses were seen in 50% (95% confidence limits: 24.4-67.8). One patient achieved a complete response. Objective response was observed in patients with visceral metastatic disease and who had received anthracyclin-containing regimens in previous chemotherapy. Median survival after therapy was 55 weeks. Median time to progression was 23 weeks. Hematologic toxicity was limiting. Cisplatin plus etoposide is an active combination in advanced breast cancer.

ISSN:0030-2414    

DOI:10.1159/000227364

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

Ovarian sex cord stromal tumors are usually indolent neoplasms that are generally confined to one or both ovaries at the time of diagnosis. The overall prognosis for these women is good though advanced or recurrent tumors occasionally occur. In such instances, if the tumor is localized, surgical or radiation therapy often provides good results; however, diffuse intra-abdominal disease is uncommon and difficult to treat effectively. Recently, synthetic gonadotropin releasing hormone (GnRH) analogue therapy has been advocated as an effective therapy with low toxicity. We report on 2 women whose advanced recurrent ovarian cord stromal tumors failed to respond to repetitive surgical, chemotherapeutic, and GnRH therapies. In these 2 cases, GnRH therapy was not successful in controlling diffuse spread of two separate gonadal stromal tumors. Systemic toxicity was minimal.

ISSN:0030-2414    

DOI:10.1159/000227365

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

Fifteen patients with advanced solid tumors of various types were treated by the intratumoral administration of recombinant human tumor necrosis factor (rH-TNF). The treatment appeared to benefit the 4 cases of superficial tumors: there were 1 complete response, 1 partial response and 2 minor responses. In all 11 patients with deep-seated tumors, including 6 cases of pancreatic cancer, 4 of liver cell cancer and 1 of metastatic liver tumor, no tumor regression was observed, but progression stopped in all these tumors. Seven of the 11 with deep-seated tumors showed a decrease in tumor markers and/or the development of tumor necrosis. Fever, hypotension and fatigue were the main clinical side effects. No significant changes were found in hematologic, renal or liver parameters. These results suggest that administration of rH-TNF to the tumor site has the potential for controlling local tumor growth.

ISSN:0030-2414    

DOI:10.1159/000227366

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

We analyzed clinicopathological features and prognosis of 390 Japanese patients with gastric cancer who survived 10 years or longer after curative resection. All of the patients were treated in our clinics. One hundred and ninety-one of these patients had early gastric cancer and the other 199 had advanced gastric cancer. The mean age was 53.5 years and the male to female ratio was 2:1. The upper one-third of the stomach was less commonly involved and a partial gastrectomy was most often done. Lymph node metastasis was present in 28.7% and extensive lymph node dissection (R2 or R3) was done in 92.5% of the cases. Nine patients died with a recurrence of gastric cancer and 20 patients died with a malignancy in other organs. Curative resection with extensive lymph node dissection and, when required, combined resection of the neighboring organs does improve the survival rate for patients with either early or advanced gastric cancer. An annual follow-up examination to rule out recurrences or malignancies in other organs is to be recommended.

ISSN:0030-2414    

DOI:10.1159/000227367

出版商:S. Karger AG    

年代:1994

数据来源: Karger

摘要:

Following surgery which left no macroscopic residue, 114 patients with differentiated thyroid cancer (58 papillary, 56 follicular) were subgrouped on the basis of the dose of externally applied prophylactic postoperative radiation: group 1 received an adequate dose of radiation (≥4,500 cGy of telecobalt, ≥4,000 R of orthovoltage therapy), while group 2 received an inadequate dose of radiation (this group included non-irradiated patients). Local/regional-relapse-free survival (LRRFS), distant-metastatic-relapse-free survival (DMRFS) and total-cause-specific survival (TCSS) were calculated by means of life-table analysis for each histologic type. TCSS and LRRFS were significantly (p < 0.001) better for group 1 in papillary cancer. No difference was found in DMRFS. LRRFS was significantly (p < 0.001) better for group 1 in follicular cancer. No differences were found in TCSS and DMRFS. We conclude that (1) prophylactic postoperative external irradiation is an effective method for survival prolongation in papillary cancer, reducing local/regional recurrences, and (2) external irradiation should be considered in the postoperative management of follicular cancer, to diminish local/regional rela

ISSN:0030-2414    

DOI:10.1159/000227368

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227369

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227370

出版商:S. Karger AG    

年代:1994

数据来源: Karger

ISSN:0030-2414    

DOI:10.1159/000227371

出版商:S. Karger AG    

年代:1994

数据来源: Karger